Russ Altman is the Kenneth Fong Professor of Bioengineering, Genetics, Medicine, Biomedical Data Science and (by courtesy) Computer Science at Stanford University. His primary research interests are in the application of computing to problems relevant to medicine. Kim Branson is a senior vice president and Global Head of Artificial Intelligence and Machine Learning at GSK, where he leads the GSK.ai team, a group of nearly 100 machine learning researchers and engineers who are pioneering the application of AI to drug discovery and development. In this conversation with Stanford adjunct lecturer and STVP Director of Principled Entrepreneurship Jack Fuchs, Altman and Branson discuss how ethics and principles can shape innovation at the intersection of AI and drug development.  --------------------Stanford eCorner content is produced by the Stanford Technology Ventures Program. At STVP, we empower aspiring entrepreneurs to become global citizens who create and scale responsible innovations.CONNECT WITH USTwitter: https://twitter.com/ECorner LinkedIn: https://www.linkedin.com/company/stanfordtechnologyventuresprogram/ Facebook: https://www.facebook.com/StanfordTechnologyVenturesProgram/ YouTube: https://www.youtube.com/user/ecorner LEARN MOREeCorner Website: https://ecorner.stanford.edu/STVP Website: https://stvp.stanford.edu/Support our mission of providing students and educators around the world with free access to Stanford University's network of entrepreneurial thought leaders: https://ecorner.stanford.edu/give.

Russ Altman (Stanford University) & Kim Branson (GSK) - Principled Engineering: AI and Drug Development

Get Started

Download the App